Higher Incidence of Osteonecrosis of the Jaw (ONJ) in Patients with Metastatic Castration Resistant Prostate Cancer Treated with Anti-Angiogenic Agents-Reference-Cited by-同舟云学术

Higher Incidence of Osteonecrosis of the Jaw (ONJ) in Patients with Metastatic Castration Resistant Prostate Cancer Treated with Anti-Angiogenic Agents

Published:2009-01 Issue:2 Volume:27 Page:221-226
ISSN:0735-7907
Container-title:Cancer Investigation
language:en
Short-container-title:Cancer Investigation

Author:

Aragon-Ching Jeanny B.,Ning Yang-Min,Chen Clara C.,Latham Lea,Guadagnini Jean-Pierre,Gulley James L.,Arlen Philip M.,Wright John J.,Parnes Howard,Figg William D.,Dahut William L.

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,General Medicine

Link

http://www.tandfonline.com/doi/pdf/10.1080/07357900802208608

Reference32 articles.

1. Critical review: Updated recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patients—May 2006

2. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic

3. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases

Cited by 107 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Relationship between Medication-Related Osteonecrosis of the Jaw and CDK4/6 Inhibitors in Breast Cancer;Current Oncology;2024-01-01

2. MicroRNA in medication related osteonecrosis of the jaw: a review;Frontiers in Physiology;2023-04-26

3. Medication-induced osteonecrosis of the jaw: a review of cases from the Food and Drug Administration Adverse Event Reporting System (FAERS);BMC Pharmacology and Toxicology;2023-03-06

4. Lower Fracture Rates in Patients Treated with Radium-223, Abiraterone or Enzalutamide, When Given Concurrently with Bone Health Agents: A Real-World Analysis;Clinical Genitourinary Cancer;2022-10

5. Non-antiresorptive drugs associated with the development of medication-related osteonecrosis of the jaw: a systematic review and meta-analysis;Clinical Oral Investigations;2022-01-11